UNH — Q3 2026 Financial Report Analysis

Profit up 52% on slightly lower revenue, and full-year guidance raised again

UnitedHealth Group's third quarter of 2026 (the three months to September 30) continued the pattern of the second: the company is collecting slightly less money and keeping far more of it. Total revenue was $112.7 billion, down 0.4% from $113.2 billion a year earlier, while earnings from operations rose 52% to $6.6 billion and diluted earnings per share went from $2.59 to $4.56. Management raised its full-year 2026 outlook to at least $19.50 of earnings per share (at least $20.50 adjusted), above the top of the range it gave in July.

This analysis is based on the earnings release filed with an 8-K on October 13, 2026. The full quarterly report (10-Q) with management's detailed discussion has not been filed yet, so some points below, such as how much of last year's quarter was affected by reserve changes, can't be checked yet.

At a glance

• Medical care ratio 88.4%, down from 89.9%. UnitedHealth paid out 88.4 cents in medical claims for every dollar of premium, 1.5 cents less than a year ago. On $87 billion of quarterly premiums, that gap is worth about $1.3 billion of profit.
• $610 million of the improvement came from earlier estimates being too high. Claims for care given earlier in 2026 came in below what the company had set aside for them. That is about 0.7 points of the 88.4% ratio, so the underlying ratio was roughly 89.1%.
• 1.8 million fewer members than a year ago. UnitedHealthcare covered 48.3 million people at September 30, down 3.6%, including 830,000 fewer Medicare Advantage members. The profit recovery comes from repricing and shrinking, not from growth.

The numbers

Operating margin is earnings from operations as a share of revenue: what is left after paying claims and running the business, before interest and tax. For a company with $113 billion of quarterly revenue, each point of margin is worth more than $1 billion.

Where the margin came from: claims grew more slowly than premiums shrank

The medical care ratio (MCR) is the share of premium revenue paid out as medical claims. It is the most-watched number for a health insurer, because the company's own costs, interest, tax and profit all have to fit in what's left.

Premium revenue fell 2.1% to $87.1 billion, but medical costs fell faster, by 3.7% to $77.0 billion. The release gives the reasons as "medical cost management initiatives, benefit design changes and pricing discipline, as well as care delivery enhancements." Put simply, UnitedHealth raised prices, trimmed what its plans cover, and dropped business that was losing money. The membership table shows the last part: commercial plans where UnitedHealth carries the claims risk fell 10.2% to 7.6 million people, and Medicaid fell 10.3% to 6.7 million. Plans where employers carry the risk and UnitedHealth only administers them grew 3.2% to 22.2 million. Premium revenue falling less (2.1%) than medical membership (3.6%) also points to higher prices per member.

The $610 million of favorable reserve development needs care. Insurers book an estimate of claims for care that has happened but hasn't been billed yet. When the bills arrive below the estimate, the difference flows into the current quarter's profit. The release says this $610 million relates to "2026 dates of service", meaning the first half of this year was reserved more cautiously than it needed to be. It is real money, but it won't repeat, and without it the MCR would have been about 89.1% rather than 88.4%. Using the quarter's 22.2% tax rate, our rough estimate is that it added about $0.53 to EPS. The Q2 release had a similar $860 million of reserve development, so two quarters in a row have benefited from earlier estimates being too high.

Running costs also fell. The operating cost ratio (administrative and running costs as a share of revenue) dropped to 12.8% from 13.5%, and operating costs fell 5.6% to $14.4 billion. Management credits "realized operating efficiencies", partly offset by spending on technology, including what it calls "operational agentification" (automating administrative work with AI agents).

Segments: both halves improved, but Optum Health is still thin

UnitedHealthcare. Earnings from operations rose 57% to $2.8 billion on revenue down 0.8%. Medicare & Retirement revenue fell 2.2% to $42.4 billion "due to changes in membership and product mix"; the release says Medicare Advantage seniors (including some complex Medicaid-linked groups) have fallen by 935,000 since the end of 2025. Medicare Advantage membership did tick up by 40,000 between June and September. Employer & Individual revenue grew 1.7% to $20.2 billion, but that business lost 165,000 people in the quarter to "employer attrition." On the quality side, at least 69% of Medicare Advantage members are in plans rated 4 stars or higher for 2027, which management called in line with expectations. Star ratings matter because they set the bonus payments the government pays these plans.

Optum Health (UnitedHealth's doctor groups and clinics, many paid a fixed amount per patient under "value-based care" contracts) went from barely breaking even to a 3.2% margin. Revenue fell 10% because Optum stopped serving value-based patients "in markets where Optum lacked sufficient value-based care presence to sustain its clinicians", in other words it left markets where it was too small to make the model work. Two caveats: $735 million of reported earnings includes $85 million of gains from selling businesses and $62 million of other items, so the adjusted figure is $588 million (a 2.6% margin). And the margin fell from the 5.1% in Q2 that our previous report described.

Optum Insight had the biggest margin jump, to 23.4% from 17.3%, credited to "enhanced product offerings and operational efficiencies." Optum Rx, the pharmacy benefit manager (the middleman that negotiates drug prices and processes prescriptions for health plans), grew earnings 11% even though it filled 5.1% fewer adjusted prescriptions (393 million vs 414 million). The release credits "continued adoption of biosimilars" (cheaper copies of biologic drugs, which tend to earn the PBM more) and lists the lost volume as coming from UnitedHealthcare's own membership decline.

What the headline numbers hide

• Some of the 52% operating growth is one-offs. GAAP earnings from operations of $6,563 million include $224 million of net gains from selling businesses (after $76 million of losses on the South American operations being sold) and $74 million of other items, mostly a $95 million release of a provision for contracts expected to lose money. The company's own adjusted earnings from operations, which strip these out, were $6,265 million, up 45% rather than 52%. Take out the $610 million of reserve development as well and the rise is about 31%. We can't tell yet whether Q3 2025 also had reserve development, because this release doesn't say.
• Adjusted EPS is above GAAP EPS only because of amortization. Adjusted EPS of $4.69 adds back $0.41 of amortization (the accounting write-down of past acquisitions), then removes $0.16 of divestiture gains and $0.08 of other gains, plus a $0.04 tax effect. In this quarter the adjustments take out gains as well as add back costs, which is the less flattering direction for the company.
• Almost none of the EPS growth came from buybacks or tax. Diluted shares fell only 0.7% (902 million vs 908 million). The tax rate went up, to 22.2% from 21.2%, and interest expense fell just $40 million. EPS growth of 76% is almost all operating profit.
• Cash flow is solid for the year, softer for the quarter. Third-quarter operating cash flow was $5.1 billion, 1.2 times net earnings. Over nine months it was $25.1 billion, 1.5 times net earnings of $16.5 billion, already above the roughly $24 billion full-year cash flow management guided to in July.
• No sign of earnings boosted by slow collections or under-reserving. Receivables fell to $20.5 billion from $23.0 billion at the end of 2025, and days sales outstanding (how long customers take to pay) improved to 16.9 days from 18.6. Days claims payable, a rough gauge of how much the company holds back for unpaid claims, rose to 47.0 from 46.2 a year ago. A higher number suggests reserves are no thinner than before.
• Debt went the wrong way in the quarter. The debt-to-capital ratio (debt as a share of debt plus shareholders' equity) rose to 41.7% from 41.2% at June 30, even though management still targets about 40% by year-end. Long-term debt is down $3.6 billion since December, so the year-to-date trend is lower. The company has bought back $5.0 billion of stock and paid $6.2 billion of dividends so far this year.
• Two costs the release doesn't size. UnitedHealth has committed to "voluntarily eliminating and rebating profits" on its individual Affordable Care Act plans for 2026, returning the money to about 1 million members, and has committed $1 billion to the United Health Foundation, $400 million of which was booked earlier this year (and excluded from adjusted figures). The release doesn't say how much the ACA rebate costs or where it is recorded.

Did last time's read hold up?

Our Q2 report pointed out that July's guidance (a full-year MCR of 88.1%, give or take 0.25 points, against 85.3% in the first half) implied a second-half MCR near 91%. We said that if this conservatism proved unnecessary, "the upside lands in Q4." Q3 came in at 88.4%, far below 91%, and guidance went up in October rather than waiting for Q4, so the conservatism looks at least partly unnecessary. The caveat is the same one we flagged in Q2: about 0.7 points of Q3's ratio was reserve releases again, so the ratio from claims actually incurred in the quarter was closer to 89%. That is still well below the implied 91%.

Takeaway: UnitedHealth's recovery is now two quarters old and holding: the medical care ratio was 1.5 points lower than a year ago even in a seasonally heavier quarter, and guidance went up by about $0.75 at the midpoint. But each quarter has relied on releasing reserves set aside earlier in the year ($860 million in Q2, $610 million in Q3), and the guidance implies a much weaker Q4. The real test is 2027, when there will be no more 2026 reserves to release and pricing has to keep up with medical costs on its own.

Guidance and our read

The new floor of $20.50 adjusted EPS is $0.50 above July's top end. The arithmetic matters more than the headline: nine-month adjusted EPS is already $18.30, so "at least $20.50" requires only $2.20 in the fourth quarter, less than half of the $4.69 just earned. On a GAAP basis, the floor needs $2.00 against $17.50 already booked. Part of the gap is seasonal. Medical costs usually rise late in the year as members use up their deductibles, and the design of Medicare drug plans pushes more of the cost onto the insurer later in the year. But part of it reflects management keeping room to beat its own numbers, as it did after Q2. The release doesn't restate the full-year MCR target, so we can't yet tell what fourth-quarter ratio the company is assuming.

Our read: the 2026 repricing has worked faster than the market feared earlier in the year, and the evidence is now in both businesses. UnitedHealthcare's margin is up 1.2 points, and Optum Health has gone from breaking even to profitable. What the release can't yet show is whether that holds without the help of reserve releases and with a smaller membership base. The things to watch are the 10-Q's reserve tables (likely filed in late October or early November), which will show how much prior-year development, if any, was in Q3 2025's comparison; the 2027 guidance in January; and whether the Medicare Advantage membership decline has stopped, which the small rise between June and September hints at.